Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections—are they applicable today?  by Caínzos, M.
REVIEW 10.1111/j.1469-0691.2008.02123.x
Review of the guidelines for complicated skin and soft tissue infections
and intra-abdominal infections—are they applicable today?
M. Caı´nzos
Hospital Clı´nico Universitario, Medical School, Santiago de Compostela, Spain
ABSTRACT
Difﬁcult-to-treat infections in surgical patients, such as serious skin and soft tissue infections (SSTIs) and
complicated intra-abdominal infections (cIAIs), are the cause of signiﬁcant morbidity and mortality, and
carry an economic burden. These surgical site infections are typically polymicrobial infections caused by
a plethora of pathogens, which include difﬁcult-to-treat organisms and multiresistant Gram-positive
and Gram-negative strains. Optimal management of SSTIs and cIAIs must take into account the
presence of resistant pathogens, and depends on the administration of appropriate antimicrobial
therapy (i.e. the correct spectrum, route and dose in a timely fashion for a sufﬁcient duration as well as
the timely implementation of source control measures). Treatment recommendations from the Infectious
Diseases Society of America and the Surgical Infection Society are available for guidance in the
management of both of these infections, yet the increased global prevalence of multidrug-resistant
pathogens has complicated the antibiotic selection process. Several pathogens of concern include
methicillin-resistant Staphylococcus aureus, responsible for problematic postoperative infections, espe-
cially in patients with SSTIs, extended-spectrum b-lactamase-producing Gram-negative bacteria,
including CTX-M-type-producing Escherichia coli strains, and multidrug-resistant strains of Bacteroides
fragilis. New empirical regimens, taking advantage of potent broad-spectrum antibiotic options, may be
needed for the treatment of certain high-risk patients with surgical site infections.
Keywords Complicated intra-abdominal infections, complicated skin and soft tissue infection, novel
antimicrobials, resistant pathogens, treatment guidelines
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INTRODUCTION
Complicated intra-abdominal infections (cIAIs)
and serious skin and soft tissue infections (SSTIs)
are associated with considerable patient morbid-
ity, mortality and escalating healthcare expendi-
tures, due to the need for additional surgery and
antimicrobial therapy, prolonged hospital stay
and months of convalescence [1–3]. As such, the
signiﬁcant impact of these infections on patient
outcome and survival is an important reason to
reassess the management of these infections and
the appropriate role of antimicrobial therapy.
Furthermore, a better means of identifying and
treating higher-risk patients with infections
caused by potentially multiply antibiotic-resistant
bacteria is needed.
By deﬁnition, cIAI is an infectious process that
proceeds beyond the organ that is the source of
the infection, and causes either localized perito-
nitis, also referred to as abdominal abscess, or
diffuse peritonitis, depending on whether the
patient’s host responses can contain the process
within the abdominal cavity [4]. Patients are
considered to have complicated (c)SSTIs when
there is a need for surgical intervention, if deep
soft tissue involvement is suspected or conﬁrmed,
and ⁄ or when the patient has a complicating
condition such as diabetes mellitus, peripheral
vascular disease, or peripheral neuropathy [5].
Both cIAIs and cSSTIs are typically polymi-
crobial infections caused by a wide range of
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possible pathogens, which include difﬁcult-to-
treat organisms and multiresistant Gram-positive
and Gram-negative strains [6,7]. IAIs are most
commonly caused by multiple microorganisms
that compose the intestinal ﬂora, such as aerobes
and facultative and obligate anaerobes, with
Enterobacteriaceae (e.g. Escherichia coli and Klebsi-
ella pneumoniae), enterococci and Bacteroides fra-
gilis being isolated most often [4,7]. It is
noteworthy that an increasing number of mem-
bers of the gastrointestinal ﬂora possess multiple
resistance factors that express antimicrobial resis-
tance (e.g. via extended-spectrum b-lactamase
(ESBL) production) [8]. Outbreaks due to ESBL-
producing E. coli and K. pneumoniae can nega-
tively affect patient outcome, emphasizing the
need for the judicious use of antimicrobials in
order to minimize the spread of the infectious
agents [8].
Likewise, the aetiological agents of cSSTIs also
commonly comprise an array of organisms, often
with multidrug-resistance phenotypes. A large
surveillance study from North America, Europe
and Latin America, analysing over 2500 isolates,
found that the following organisms were most
commonly implicated as causes of cSSTIs: Staphy-
lococcus aureus (39.9%), Pseudomonas aeruginosa
(12.1%), E. coli (9.7%), Enterococcus spp. (7.7%),
Klebsiella spp. (5.8%), Enterobacter spp. (5.6%),
coagulase-negative staphylococci (4.2%), Proteus
spp. (3.7%), Streptococcus spp.(2.6%), Acinetobacter
spp. (2.2%) and Serratia spp. (2%) [9]. In North
America, the prevalence of these pathogens varied
slightly: S. aureus, 45.9%; P. aeruginosa, 10.8%;
E. coli, 7%; Enterococcus spp., 8.2%; Klebsiella spp.,
5.1%; Enterobacter spp., 5.8%; coagulase-negative
staphylococci, 3.4%; Proteus spp., 3.2%; Streptococ-
cus spp., 2.7%;Acinetobacter spp., 1.6%; andSerratia
spp., 2%. This surveillance study also revealed that
the rate of methicillin-resistant S. aureus (MRSA)
was 27.2% overall (29% inNorthAmerica) [9]. The
emergence of community-associated MRSA is also
alarming, especially in patients with cSSTIs [10]. A
retrospective meta-analysis of surveillance studies
conducted in Europe conﬁrmed that S. aureus,
coagulase-negative staphylococci, E. coli and
P. aeruginosa were the most common pathogens
associatedwith cSSTIs ⁄ surgical site infections [11].
Certain patient risk factors, such as a history of
intravenous drug use, must also be considered
when attempting to predict the possible aetiologies
of cSSTIs [12].
Successful management of cIAIs and cSSTIs is
dictated, in part, by the likely presence of resistant
pathogens, and depends on the administration of
adequate antimicrobial therapy, and the timely
implementation of source control measures [4,7].
Treatment recommendations are available to
guide the clinician in the management of both of
these infections [4,13,14]. However, because cSS-
TIs and cIAIs caused by multidrug-resistant
pathogens have become more common over the
last decade, alternative empirical treatments not
currently outlined in the published guidelines
may need to be considered for at-risk patients.
The primary purpose of this article is to discuss
the impact of surgical site infections, including
cSSTIs and cIAIs, on patient outcomes, to review
the current treatment guidelines for surgical site
infections, and to discuss the current treatment
guidelines for cSSTIs and cIAIs in the context of
the patterns of emerging resistance in Europe and
the potential for monotherapy in empirical regi-
mens.
COMPLICATED SKIN AND SOFT
TISSUE INFECTIONS ⁄ SURGICAL
SITE INFECTIONS
Surgically induced soft tissue surgical site infec-
tions (SSIs) are typically divided into the following
categories: superﬁcial incisional SSIs, deep inci-
sional SSIs, and organ ⁄ space SSIs [15]. Superﬁcial
incisional SSIs involve only the subcutaneous
space, between the skin and the underlying
muscular fascia, and occur within 30 days of the
index operation. A deep incisional SSI involves the
deep layers of soft tissue (e.g. fascia andmuscle) in
the incision, and typically occurs within 30 days
following the surgical procedure. An organ ⁄ space
SSI is similar to a deep incisional SSI, except that it
may involve any part of the anatomy (organs or
spaces) other than the incision opened during the
operation.
Assessing the total impact of cSSTIs ⁄ SSIs on
patient morbidity and overall outcome is difﬁcult
because of incomplete data collection and report-
ing. A retrospective analysis of reported surgical
site infections conducted in Europe attempted to
calculate the incidence of these infections [11].
The estimated incidence varied widely, from
1.5% to 20%, suggesting that the true rate of
SSTIs is currently unknown and is probably
under-reported due to inconsistencies in data
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collection methods and surveillance criteria, and
to wide variations in the surgical procedures
investigated. The frequency of surgical site infec-
tions is clearly related to the category of opera-
tion, with clean and low-risk operations having
the lowest rate of infection, and contaminated and
high-risk operations having greater infection rates
[16]. In any event, SSIs carry a signiﬁcant eco-
nomic burden, ranging from 1.47 to 19.1 billion
euros annually in the European countries [11].
Although the true incidence of cSSTIs per
surgical site is unclear, it is well appreciated that
these infections are associated with substantial
morbidity and can be potentially life-threatening
in the surgical patient. A surgical site infection
surveillance network implemented in 1997 among
general surgical units in northern France which
volunteered to participate is a source of important
evidence concerning patient outcomes [1].
For 3 months each year, all patients who under-
went a surgical procedure were consecutively
reviewed for perioperative condition and were
traced for outcome with a 30-day follow-up.
Among the 38 973 surgical patients included over
a 3-year period, 1344 (3.4%) patients developed an
SSI, 568 of whom died (1.5%). Organ ⁄ space SSIs
and deep incisional SSIs were associated with
higher mortality rates (5.7% and 13.2%, respec-
tively) and required re-operation more frequently
(44.0% and 53.2%, respectively) than did superﬁ-
cial incisional SSIs (4.2% and 8.6%, respectively).
The incidence of mortality associatedwith surgical
site infections was notably high following gastro-
intestinal procedures. Following 15 665 gastroin-
testinal procedures, the incidence of surgical site
infectionswas 4.9%, with overall mortality at 2.2%
and case-fatality at 7.2%. For all surgical proce-
dures resulting in SSIs, 38% of the deaths in these
patients were attributable to infection.
cSSTIs are associated with signiﬁcant underly-
ing disease that often lowers the likelihood of
response to treatment. The Infectious Diseases
Society of America (IDSA) has recently published
several classiﬁcation schemes and practice guide-
lines for the diagnosis and management of cSS-
TIs ⁄ SSIs, including compromised hosts of all age
groups [14]. Most patients with cSSTIs ⁄ SSIs will
require hospitalization or a prolonged stay, and
additional surgical intervention for conﬁrmation
of bacterial aetiology and drainage of infected
material. Importantly, bacterial culture and sus-
ceptibility testing should be undertaken for
patients with signs and symptoms of systemic
toxicity, e.g. fever, tachycardia, and hypotension.
Aggressive and directed intravenous antimicro-
bial therapy will be necessary for patients with
severe infections. Antibiotic treatment recommen-
dations were based on the surgical site infection
category and the location of surgical intervention.
SSIs that involve the gastrointestinal tract or the
female genital tract can be expected to have a
mixed Gram-positive and Gram-negative ﬂora
with both facultative and anaerobic organisms.
The antimicrobials typically considered to be
optimal for treatment of intra-abdominal infection
are appropriate choices. Several single agents are
recommended for incisional SSIs involving the
intestinal or genital tract, e.g. cefoxitin, ampicil-
lin–sulbactam, piperacillin–tazobactam and imip-
enem–cilastatin (Table 1) [14]. Recommended
combination regimens include ﬂuoroquinolones,
third-generation cephalosporins, and aminogly-
cosides in conjunction with clindamycin, metro-
nidazole or a b-lactam–b-lactamase inhibitor
combination [14].
For non-intestinal sites of operation (exclud-
ing the axilla or the perineum), oxacillin or a
ﬁrst-generation cephalosporin is recommended
(Table 2) [14]. These agents provide coverage
against the expected pathogens, e.g. S. aureus
(other than MRSA) and streptococcal species.
Clindamycin is an acceptable alternative for
patients with a history of b-lactam hypersensi-
tivity; however, there is a high potential of
cross-resistance and emergence of resistance in
erythromycin-resistant strains and of inducible
resistance in MRSA [10]. Where the rate of
infection with MRSA is high, vancomycin,
Table 1. Antibiotic choices for incisional surgical site
infections: intestinal or genital tract site of operation
Single agents Combination agents
Cefoxitin Facultative and aerobic
activity
Ceftizoxime Fluoroquinolone
Ampicillin–sulbactam Third-generation
cephalosporin
Ticarcillin–clavulanate Aztreonam
Piperacillin–tazobactam Aminoglycoside
Imipenem–cilastatin Anaerobic activity
Meropenem Clindamycin
Ertapenem Metronidazolea
Chloramphenicol
Penicillin agent plus
b-lactamase inhibitor
aDo not combine aztreonam with metronidazole, because this combination has no
activity against Gram-positive cocci.
Adapted from Ref. [14].
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daptomycin or linezolid are currently recom-
mended, pending results of culture and suscep-
tibility tests. However, the appearance of
vancomycin-, linezolid- and daptomycin-resis-
tant strains suggests that new options are
needed [17–24]. For infections involving the
axilla or the perineum, cefoxitin and ampicil-
lin–sulbactam are the agents of choice [14].
Other monotherapies, as recommended above
for intestinal and genital tract sites of operation,
may also be used.
Treatment of necrotizing infections of the skin,
fascia and muscle require broad-spectrum anti-
microbials (e.g. piperacillin–sulbactam, ciproﬂox-
acin, or meropenem plus clindamycin or
metronidazole) (Table 3) [14]. Appropriate agents
for patients with severe penicillin hypersensitivity
include clindamycin or metronidazole with an
aminoglycoside or ﬂuoroquinolone. The IDSA
recommendations also provide pathogen-directed
regimens for the treatment of necrotizing cSSTIs
(Table 4) [14].
INTRA-ABDOMINAL INFECTIONS
Intra-abdominal infections are among the most
common infections in general surgery and are
frequently severe medical conditions, involving
signiﬁcant morbidity and mortality and carrying
a burden of resource use [4]. In a retrospective
study of 604 consecutive patients who underwent
emergency surgery for unequivocal intra-abdom-
inal infections, a morbidity rate of 59% and a
mortality rate of 21% were reported [25].
These data support the idea that optimal
management must include early diagnosis,
appropriate surgical intervention, and adequate
antimicrobial therapy [4]. The consequences of
delayed or inappropriate antimicrobial treatment
can be severe, leading to an increased risk of
death, necessity of re-operation, or prolonged
hospitalization.
Although early adequate surgery or drainage
remain the cornerstones of management of
intra-abdominal infections and impact on patient
outcome, the early administration of adequate
empirical broad-spectrum antimicrobial therapy
further inﬂuences the rates of patient morbidity
and mortality. A prospective cohort study of 2000
subjects established a statistically signiﬁcant
relationship between inadequate antimicrobial
treatment of infections and hospital mortality in
patients requiring intensive-care unit admission
[26]. Speciﬁcally, 25.8% (169 of 655) of patients
assessed as having either community-acquired or
nosocomial infections were judged to have
received inappropriate empirical therapy. Inade-
quate antimicrobial treatment of infection was
reported most often among patients with nosoco-
mial infections that developed after treatment of a
community-acquired infection (45.2%), followed
by patients with nosocomial infections alone
(34.3%) and patients with community-acquired
infections alone (17.1%) (p <0.001). The infection-
related mortality rate in patients with proven
infection who were receiving inadequate antimi-
crobial therapy (42.0%) was signiﬁcantly greater
than the infection-related mortality rate in
infected patients who were receiving adequate
antimicrobial therapy (17.7%) (p <0.001). A
history of prior antimicrobial therapy was an
important risk factor for the administration of
inadequate antimicrobials in this patient cohort.
Another study, among 425 patients requiring
surgery for community-acquired secondary peri-
tonitis, reported that 13% of the patients had
received inappropriate initial empirical antibiotic
Table 2. Antibiotic choices for incisional surgical site
infections: non-intestinal site of operation
Trunk and extremities away from axilla or perineum
Oxacillin
First-generation cephalosporin
Axilla or perineum
Cefoxitin
Ampicillin–sulbactam
Other single agents as described for intestinal and
genital operations (see Table 1)
Adapted from Ref. [14].
Table 3. Treatment of necrotizing infections of skin,
fascia, and musclea
First-line antimicrobial
agent, by infection type Adult dosage
Mixed infection
Ampicillin–sulbactam
or
1.5–3 ⁄ 0 g every 6–8 h IV
Piperacillin–tazobactam
plus
3.375 g every 6–8 h IV
Clindamycin
plus
600–900 mg ⁄ kg every 8 h IV
Ciproﬂoxacin 400 mg every 12 h IV
Imipenem–cilastatin 1 g every 6–8 h IV
Meropenem 1 g every 8 h IV
Ertapenem 1 g every 24 h IV
Cefotaxime
plus
2 g every 6 h IV
Metronidazole
or
500 mg every 6 h IV
Clindamycin 600–900 mg ⁄ kg every 8 h IV
aIf Staphylococcus infection is present or suspected, add an appropriate agent.
Adapted from Ref. [14].
12 Clinical Microbiology and Infection, Volume 14, Supplement 6, December 2008
 2008 The Author
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 6), 9–18
therapy [27]. The same study also conﬁrmed that
patients were more likely to have clinical success
if initial antibiotic therapy was appropriate
(78.6%) than if inappropriate regimens were used
(53.4%) [27]. Not surprisingly, this study also
found that administration of appropriate antimi-
crobial therapy, coupled with clinical success, was
linked with a 6-day shorter length of hospital stay.
A third retrospective study by Bare et al., con-
ducted in northeast Spain in patients with com-
munity-acquired intra-abdominal infections,
reported that 14% of patients received inappro-
priate initial empirical antibiotic therapy [28].
They also conﬁrmed the ﬁndings of others that
inappropriate antibiotic therapy led to less
favourable clinical outcomes.
Choosing appropriate empirical antimicrobial
therapy requires an appreciation of the microbi-
ology of cIAIs. The aetiology of peritonitis
depends on whether the infection is primary (also
known as spontaneous peritonitis), secondary, or
tertiary. Primary peritonitis is less common and
usually occurs in the presence of ascites without
an evident source of infection. However, when
infection occurs, it is typically due to a single
organism, e.g. E. coli, Klebsiella spp., Streptococcus
spp., or Enterococcus spp. [29,30]. Secondary peri-
tonitis occurs when the peritoneal space is con-
taminated by endogenous microﬂora secondary
to loss of integrity of the gastrointestinal tract. In
most clinical settings, two to three aerobic species
and one to two anaerobic species are identiﬁed in
patients with secondary peritonitis. As such, these
polymicrobial infections typically include the
aforementioned organisms, along with B. fragilis
and Pseudomonas spp., depending on the level of
gastrointestinal disruption [29,30]. Tertiary peri-
tonitis, which is typically caused by multiple
pathogens, may include all of the previously
mentioned organisms in addition to Staphylo-
coccus epidermidis and Candida sp. [29]. Not
unexpectedly, community-acquired peritoneal
infections often differ substantially in the micro-
bial causes of infection from those acquired in the
nosocomial setting. E. coli and streptococci tend to
be isolated more commonly in patients with
community-acquired peritonitis, whereas Entero-
coccus spp., Enterobacter spp., S. aureus and coag-
ulase-negative staphylococci are more common in
patients with nosocomial peritonitis [31].
The microbiology of SSIs was evaluated in a
2-year prospective study of 2552 patients who
underwent either elective (58%) or emergency
(42%) surgery. In total, 19.6% (n = 501) of the
patients developed postoperative infections, of
which 61.3% had a conﬁrmed aetiology. Among
these patients, 84 of 501 had intra-abdominal
infections. Gram-negative bacteria were isolated
more often (56%) than Gram-positive bacteria
(29%), followed by anaerobic ﬂora (13%). This
surveillance study found that the most commonly
isolated organisms (n = 78) in patients with cIAI
were E. coli (32.5%), Enterococcus (15.7%) and
Enterobacter cloacae (7.2%) [32].
The guidelines from the IDSA, the Surgical
Infection Society, the American Society for Micro-
biology and the Society of Infectious Disease
Pharmacists contain evidence-based recommen-
dations for selection of antimicrobial therapy for
adult patients with cIAIs [4,13,33]. In general,
intra-abdominal infections may be managed
with a variety of single-agent regimens (e.g.
Table 4. Pathogen-directed treatment of necrotizing infections of skin, fascia and muscle
First-line antimicrobial agent,
by infection type Adult dosage
Agents for patients with severe
penicillin hypersensitivity
Streptococcus infection
Penicillin
plus
2–4 MU q 4–6 h IV (adults) Vancomycin, linezolid, daptomycin
or quinupristin–dalfopristin
Clindamycin 600–900 mg ⁄ kg every 8 h IV
Staphylococcus aureus infection
Nafcillin 1–2 g every 4 h IV Vancomycin, linezolid, daptomycin
or quinupristin–dalfopristin
Oxacillin 1–2 g every 4 h IV
Cefazolin 1 g every 8 h IV
Vancomycin 30 mg ⁄ kg ⁄day in two divided doses IV
Clindamycina 600–900 mg ⁄ kg every 8 h IV
Clostridium infection
Clindamycin 600–900 mg ⁄ kg every 8 h IV
Penicillin 2–4 MU every 4–6 h IV
aClindamycin is bacteriostatic; potential for cross-resistance and emergence of resistance in erythromycin-resistant strains; inducible resistance in methicillin-resistant
S. aureus.
Adapted from Ref. [14].
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ampicillin–sulbactam, ertapenem, imipenem–
cilastatin, meropenem) and multiple-agent regi-
mens (e.g. cefuroxime ⁄ third- or fourth-generation
cephalosporin or ciproﬂoxacin plus metronida-
zole), depending on the type of infection (com-
munity-acquired or nosocomial) and the severity
of the infection (mild ⁄moderate or severe)
[4,13,33]. According to available data, no antimi-
crobial regimen has been consistently demon-
strated to be superior or inferior [4]. However,
monotherapy with broad-spectrum antimicrobials
has certain advantages, including a reduction in
the potential for toxicity or drug interactions
[34,35], as well as ease of administration [36].
Speciﬁc recommendations put forth in the
recent treatment guidelines [4,13,33], although
based on the best available evidence, must be
individualized according to local resistance data
and patient-speciﬁc factors. Importantly, most of
the recommended antimicrobial regimens have
been tested in prospective randomized con-
trolled trials in patients with community-ac-
quired cIAIs. For patients with mildly to
moderately severe community-acquired infec-
tions, antimicrobials that have a narrower spec-
trum of activity, e.g. ampicillin–sulbactam,
cefazolin or cefuroxime plus metronidazole,
ticarcillin–clavulanate, ertapenem and ﬂuoroqui-
nolones plus metronidazole, are considered to be
reasonable options (Table 5) [4,13,33]. These
agents are favoured because they are more
cost-effective and are often less toxic than more
potent, broad-spectrum agents, which should be
reserved for more serious infections. Most
patients with less severe community-acquired
infections will experience full recovery following
adequate source control and appropriate antimi-
crobial therapy.
Because higher-risk patients with cIAIs (e.g.
those with higher APACHE II scores, equal to or
greater than 15, poor nutritional status, signiﬁ-
cant cardiovascular disease, in a situation where
adequate source control cannot be provided) are
more likely to fail therapy because of resistant
organisms, antimicrobial regimens with broader
coverage of Gram-negative aerobic ⁄ facultatively
anaerobic organisms are recommended.
Agents used to treat nosocomial postoperative
infections must also provide coverage against
P. aeruginosa, Enterobacter spp., Proteus spp.,
MRSA, enterococci, and Candida spp. Antimicro-
bial regimens with expanded spectra include
meropenem, imipenem–cilastatin, piperacillin–ta-
zobactam, once-daily aminoglycoside or aztreo-
nam, ciproﬂoxacin plus clindamycin or
metronidazole, and a third- or fourth-generation
cephalosporin plus clindamycin or metronida-
zole (Table 5) [4,13,33]. If P. aeruginosa is a
known or likely causative organism, higher
doses of some agents may be required to ensure
adequate coverage. Additional coverage, e.g. by
vancomycin, may be needed if there is a high
suspicion of MRSA. However, the appearance of
vancomycin-resistant S. aureus escalates the need
for new ﬁrst-line therapies that are effective
against MRSA [17]. Although routine coverage
for enterococci is discouraged for most patients
with cIAIs, it seems prudent for patients with
serious nosocomial infections, despite the fact
that there are few data showing that such
coverage improves outcome [13]. Well-designed
studies are needed to compare conventional and
newer antimicrobials in patients with nosocomi-
ally acquired cIAIs, as few studies have evalu-
ated the differences in clinical outcome in
higher-risk patients. Overall, the choice of anti-
microbial therapy for patients with nosocomial
surgical infections must take into consideration
the resistance patterns of likely pathogens, the
patient’s history of prior antimicrobial exposure,
and the results of the Gram stain of infected
peritoneal ﬂuid, whenever possible.
ORGANISM-SPECIFIC RESISTANCE
AND CSSTIS AND CIAIS
The increasing prevalence of resistant pathogens
in healthcare settings raises challenges for the
treatment of patients with complicated, surgery-
related infections. Several pathogens of concern
include MRSA, which has emerged as the leading
cause of postoperative infection, especially in
patients with cSSTIs, ESBL-producing Gram-neg-
ative bacteria, including CTX-M-type-producing
strains, and multidrug-resistant strains of B. fra-
gilis. Community-associated MRSA is also a
pending cause of concern in patients with SSIs.
Infection with each of these organisms is associ-
ated with a higher risk of negative outcome,
postoperative consequences, increased length of
hospital stay, and increased utilization of hospital
resources. The development of new classes of
antibiotics that are effective against these problem
pathogens is needed.
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A retrospective cohort analysis found that
methicillin resistance was independently associ-
ated with increased mortality and hospital charges
among patients with S. aureus SSIs [37]. This
analysis included 193 uninfected control subjects,
121 patients with SSIs due to MRSA, and 165
patients with methicillin-susceptible S. aureus
(MSSA) infections. Patients infected with MRSA
had a three-fold greater 90-day mortality rate
(20.7%) than did patients infected with MSSA
(6.7%; p <0.001). Infection with MRSA was also
associated with a greater duration of hospitaliza-
tion after infection (median additional days, 5;
p <0.001). MRSA-associated infections also led to
higher healthcare expenses. Median hospital
charges were $92 363 for patients with MRSA
vs. $52 791 for patients with MSSA (p <0.001).
Furthermore, there were 1.19-fold increases in
hospital charges for patients with MRSA SSIs
(p 0.03) and mean attributable excess charges of
$13 901 per SSI as compared with patients infected
with MSSA. The adverse clinical and economic
outcomes associated with MRSA SSIs can be
linked, in part, to the availability of only subop-
timal antimicrobial agents for this pathogen.
Lautermann et al., in a retrospective cohort
study, evaluated the effect of ESBL-producing
E. coli and K. pneumoniae infection on clinical
outcomes [8]. Among the 33 cases that met the
criteria for infection, 25 (75.8%) had infections
due to K. pneumoniae and eight (24.2%) had
infections due to E. coli. Infection with ESBL-
producing E. coli or K. pneumoniae was signiﬁ-
cantly associated with a greater median hospital
charge accrued subsequent to infection ($66 590)
than was infection with non-ESBL-producing
E. coli or K. pneumoniae ($22 231; p 0.04). Kang
et al. found that bacteraemia due to ESBL-pro-
ducing K. pneumoniae (n = 66) was associated
with a higher rate of treatment failure at 72 h
after the initiation of treatment (35%) as com-
pared with control subjects (15%; p 0.011) [38].
Moreover, the outcome of cephalosporin treat-
ment for bloodstream infections due to ESBL-
producing K. pneumoniae was poor, even in the
case of apparently susceptible organisms. Overall,
these data demonstrate that infections with ESBL-
producing E. coli and K. pneumoniae have a sig-
niﬁcant impact on clinical outcome. Sensible use
of all antibiotics, as well as barrier precautions,
are important for their effective eradication and to
reduce spread.T
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Recent data indicate that infections caused by
ESBL-producing organisms are an emerging
problem in outpatient settings in various parts
of the world [39]. CTX-M-type-producing
strains have recently gained importance,
especially among Enterobacteriaceae. Surveys show
that ESBL-producing E. coli, including those
producing CTX-M types, exhibit co-resistance to
trimethoprim–sulphamethoxazole, tetracycline,
gentamicin, and ciproﬂoxacin [40]. The appear-
ance of these strains in the community may
threaten patient care if they are introduced into
the hospital. To date, few outbreaks have been
identiﬁed in the hospital settings; most have been
limited to urinary tract infections. Nevertheless,
hospital laboratories may need to routinely screen
for ESBL-producing Enterobacteriaceae originating
from the community so that appropriate therapy
can be prescribed and the spread of resistance
minimized.
Organisms within the B. fragilis group (now
also called intestinal Bacteroidales) are the most
frequently isolated anaerobic pathogens recov-
ered from blood and abscesses. Among patients
with anaerobic and mixed infections, they are also
among the most antibiotic-resistant isolates,
according to a US national survey (1997–2004)
[41]. That study of Bacteroidales spp. examined the
trends of susceptibility to various antibiotics in
5225 clinical isolates. Notably, isolates of B. fragilis
were those most commonly tested (52%). The
rates of resistance to clindamycin and moxiﬂox-
acin were high for these isolates, at 19% and 27%,
respectively. By contrast, the rates of resistance to
carbapenems and b-lactam–b-lactamase inhibitor
combinations were low. Remarkably, increases in
susceptibility to imipenem, meropenem, pipera-
cillin–tazobactam and cefoxitin (lower MICs)
were found for many species within the group,
suggesting that these agents are more active now
than they were several years ago. The resistance
rates for tigecycline, a novel, expanded broad-
spectrum glycylcycline, were also found to be low
and stable (5%) during the surveillance period.
For non-B. fragilis spp. (i.e. Bacteroides (now
Parabacteroides) distasonis), high MICs of all the
b-lactam agents (carbapenems, inhibitor combi-
nations, cefoxitin) and tigecycline were observed.
Overall, this surveillance found that the resistance
of B. fragilis, Bacteroides ovatus and Bacteroides
thetaiotaomicron to clindamycin increased signiﬁ-
cantly. Metronidazole and chloramphenicol were
the most potent agents tested; only one metroni-
dazole-resistant B. fragilis strain (MIC, 64 mg ⁄L),
the ﬁrst such strain in the USA, was documented
in this study.
The emergence of resistance in B. fragilis group
isolates, especially against metronidazole, has
important implications in the treatment of surgi-
cal infections. As in other cases where potentially
multiply resistant pathogens are involved, con-
tinued monitoring of susceptibility patterns is
important to ensure the desired outcome in the
treatment of infections due to Bacteroidales.
DURATION OF ANTIMICROBIAL
THERAPY FOR INTRA-ABDOMINAL
INFECTIONS
The duration of antimicrobial therapy for intra-
abdominal infections implies a difﬁcult clinical
decision. In general, there is agreement that
shorter treatment courses should be used when-
ever possible, to prevent collateral antibiotic
effects as well as the development of resistant
microorganisms. It is currently accepted that, in
some conditions, antimicrobial therapy should be
limited to 24 h or less [13]: traumatic and iatro-
genic perforations operated on within 12 h;
gastroduodenal perforations operated on within
24 h; acute or gangrenous appendicitis without
perforation; acute or gangrenous cholecystitis
without perforation; and transmural bowel per-
foration from embolic, thrombotic or obstructive
vascular occlusion without perforation or estab-
lished peritonitis or abscess.
For patients with cIAI, the recommendations
are as follows [4]: in general, antimicrobial ther-
apy should be limited to no more than 5–7 days.
Patients with localized infections identiﬁed at the
time of the initial operation, e.g. localized perfo-
ration of the appendix, may be treated with even
shorter courses of antimicrobial therapy. Antimi-
crobial therapy may be discontinued in patients
who have defervesced, who have normalizing
white blood cell counts, and who have returned to
normal gastrointestinal function. Patients with
persistent signs of systemic infection after an
initial course of antimicrobial therapy should
undergo clinical investigations to determine the
cause of the signs of persistent infection, and they
should not be subjected to prolonged antimicro-
bial therapy or arbitrary changes in antimicrobial
agents. Critically ill patients who have poorly
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controlled infections, e.g. those with tertiary
peritonitis, may beneﬁt from more prolonged
courses of appropriate antimicrobial therapy.
CONCLUSIONS
The development of surgical site-associated
infections is a serious sequela, as these infections
contribute signiﬁcantly to morbidity and mortal-
ity. In particular, cSSTIs and cIAIs are responsi-
ble for a signiﬁcant proportion of disease burden
in surgical patients. The diagnosis and manage-
ment of these infections require a high degree of
suspicion, prompt surgical intervention, and
adequate antibiotic therapy. Therapy should be
targeted at the most likely pathogens and
adjusted after culture and susceptibility test
results become available. Accordingly, current
antibiotic use needs to take into account the
increasing resistance in Gram-positive bacteria
(e.g. MRSA), Gram-negative ESBL-producing
Enterobacteriaceae (e.g. E. coli), and the growing
resistance to several antimicrobials in anaerobes.
Selection of the optimal antimicrobial regimen
must also take into account individual patient
factors, drug-speciﬁc safety proﬁles, and cost
considerations. Recognition of higher-risk pa-
tients (e.g. those with an APACHE II score >15,
of advanced age, with a non-appendiceal source
of infection, a nosocomial infection or a postop-
erative infection) is the key to achieving the
desired response, as potent broad-spectrum ther-
apy is probably needed.
Current treatment guidelines for the manage-
ment of cSSTIs and cIAIs do not reﬂect the
availability of new antibiotics, or the latest trends
in bacterial resistance. Furthermore, today’s
resistance trends frequently require the use of
multiple agents due to the polymicrobial nature
of these infections. The increased resistance of
bacteria, particularly of MRSA, ESBL-producing
Gram-negative bacteria, and the B. fragilis group,
to current antibiotics highlights the growing
need for new classes of broad-spectrum agents
for empirical therapy to treat these serious
complications in the surgical patient with mixed
infections.
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